(A) Sequence alignment of human CALHM3, CALHM2, and CALHM1, and of murine and C. elegans CALHM1. Conserved sequences are highlighted in blue and sequence conservation is mapped in a color gradient, the darkest color representing sequences with absolute identity and lighter colors representing sequences with weaker conservation. Boxes denote hydrophobic domains 1–4 (HD1–4). Stars, predicted N-glycosylation sites on human CALHM1.
(B) Phylogenetic tree including human CALHM1 (hCALHM1).

(A) Total RNA was used for RT-PCR analyses targeting CALHM1 and β-actin transcripts in multiple human tissues and brain regions.
(B) Immunofluorescence staining in CHO cells transfected with human Myc-tagged CALHM1 using anti-Myc (green) and anti-GRP78 (red) antibodies.
(C) Lysates from HT-22 cells transfected with wild type (WT) or mutated (N140A and N74A) Myc-CALHM1, were incubated in the absence (−) or presence (+) of endoglycosidase H (Endo H) or N-glycosidase F (PNGase F). Cell lysates were probed with anti-Myc (upper panels) and anti-actin (lower panels) antibodies.
(D) Cell surface-biotinylated proteins from Myc-CALHM1-transfected HT-22 cells were precipitated using immobilized avidin and probed with anti-Myc (upper panel) and anti-N-cadherin (lower panel, cell surface positive control) antibodies.

(A) Cytoplasmic Ca²⁺ measurements using Fluo-4 loading and Ca²⁺ add-back assays in HT-22 cells transiently transfected with Myc-CALHM1 or control vector. Cells were first incubated in Ca²⁺-free buffer (0 CaCl₂) and then challenged with physiological extracellular Ca²⁺ concentrations (1.4 mM CaCl₂) to monitor the progressive restoration of basal [Ca²⁺]_i. Traces illustrate the mean relative fluorescence units (RFU) +/− S.D. (shaded areas) of three independent experiments. Inset, WB of the corresponding cell lysates probed with anti-Myc antibody (Vec, vector; C, CALHM1).
(B) Peak and steady-state of [Ca²⁺]_i measurements as in (A) expressed in ΔF/F₀ (*, P<0.001; Student’s t test).
(C–H) Cytoplasmic Ca²⁺ measurements as in (A) in cells pretreated with 2-APB [50 μM, (C)], SNX-482 [0.5 μM, (D)], mibefradil [1 μM, (D)], nifedipine [10 μM, (E)], ω-conotoxin MVIIC [Conotoxin, 5 μM, (E)], dantrolene [DTL, 10 μM, (F)], xestospongin C [XeC, 2 μM, (F)], or with the indicated concentrations of CoCl₂ (G) and NiCl₂ (H). Traces in (C–H) illustrate representative measurements of 2–3 independent experiments.
(I) WB with anti-Myc (upper panels) and anti-actin (lower panels) antibodies of protein extracts obtained from cells treated as in (G) and (H).

(A) Lysates from non-transfected (NT) and Myc-CALHM1-tranfected HEK293 cells were analyzed by WB in the absence (Control) or presence of β-mercaptoethanol (+βME) using anti-Myc (two upper panels) and anti-actin (lower panel) antibodies.
(B) Lysates from HEK293 cells transfected (+) or not (−) with V5-tagged CALHM1 (V5-CALHM1) or Myc-CALHM1, were immunoprecipitated with anti-Myc antibody. Total lysates (Input, left panels) and immunoprecipitates (Anti-Myc IP, right panels) were analyzed by WB using antibodies against V5 (upper panels), Myc (middle panels), and actin (lower panels).
(C) Partial sequence alignment of human NMDAR NR2 (NMDAR2) subunits A–D and CALHM1 from various species. Sequence conservation is highlighted in a blue gradient as described in Fig. 1A. Star denotes Q/R/N site.
(D) Cytoplasmic Ca²⁺ measurements in HT-22 cells transiently transfected with control vector and WT or N72G-mutated Myc-CALHM1. Cells were treated and results analyzed as in Fig. 3A (n = 3 independent experiments). Inset, WB of the corresponding cell lysates with anti-Myc antibody.
(E) Peak of [Ca²⁺]_i measurements as in (D) expressed in ΔF/F₀ (*, P<0.001; Student’s t test).
(F) Representative current traces during voltage ramps in Xenopus oocytes injected with CALHM1 cRNA (blue and green traces) or water (red trace) in normal LCa96 solution (blue and red traces) or in Na⁺-free LCa96 solution (replaced with equimolar N-methyl-D-glucamine (NMDG); green trace).
(G) Whole-cell currents in CALHM1-expressing (blue and red traces) or control (black trace) CHO cells in response to voltage ramps before (blue trace) and after (red trace) perfusion with 100 μM Gd³⁺. Bath contained 120 mM NaCl, pipette solution contained 122 mM CsCl (see Experimental Procedures). Cell capacitances of the CALHM1-expressing and control cells were 18.5 pF and 13.0 pF, respectively.
(H) Whole-cell currents in CALHM1-expressing CHO cells (uncorrected for leakage currents) in response to voltage ramps in bi-ionic Ca²⁺/Cs⁺ solutions (20 mM Ca-aspartate in bath, 120 mM Cs-aspartate in pipette; see Experimental Procedures) before (blue trace) or after (red trace) bath addition of 100 μM Gd³⁺(C_m = 24.1 pF). Reversal potential V_rev = +8.3 ± 2.9 mV (n = 7) after correction for liquid junction potential and leakage current, indicating P_Ca : P_Cs = 5. No currents were observed in CALHM1-expressing cells with NMDG-aspartate in bath and pipette solutions (black trace; C_m = 20.5 pF).

(A and B) SwAPP₆₉₅-N2a cells were transiently transfected with control vector or with WT or P86L-mutated Myc-CALHM1. Six and half hours post-transfection, medium was changed and cells were incubated for 60 min in the absence or presence of Ca²⁺ add-back conditions as described in Experimental Procedures. Total secreted Aβ and sAPPα, and cellular APP and Myc-CALHM1 were analyzed by WB (A). Secreted Aβ1-40 and Aβ1-42 were analyzed by ELISA in the presence of Ca²⁺ add-back conditions (n = 12; Student’s t test) (B).
(C–E) APP₆₉₅-SH-SY5Y cells differentiated for 15 days with retinoic acid were treated for 3 days with Accell siRNAs directed against human CALHM1. Medium was then changed and cells were incubated for 90 min in the absence or presence of Ca²⁺ add-back conditions. Total secreted Aβ and cellular APP and actin were analyzed by WB (C). Total secreted Aβ1-x was quantified by ELISA (n = 3; Student’s t test) (D). CALHM1 mRNA levels were assayed by real-time qRT-PCR analysis. Histogram illustrates the mean relative CALHM1 expression ± S.D. (control, n = 4; CALHM1 siRNA, n = 3) (E).
(F) Five independent case-control studies were analyzed to assess the association of rs2986017 with AD risk. The allelic OR (T vs. C) was estimated in each population and in the combined one. ¹Test for heterogeneity: χ² = 2.84, df = 4, P = 0.59; Test for overall effect: Z = 6.06, P = 2.10⁻⁹ (Mantel-Haentzel method, fixed OR = 1.42 [1.27–1.59]).
(G) Whole-cell currents in CHO cells expressing WT- (blue trace; C_m = 13.2 pF) or P86L-CALHM1 (green trace; C_m = 22.9 pF) in same bi-ionic conditions as in Fig. 4H. P86L-CALHM1-expressing cells remained sensitive to block by 100 μM Gd³⁺ (red trace), but the reversal potential was shifted to more hyperpolarized voltages (V_rev = −8.9 ± 3.6 mV ; n = 6), indicating a reduced Ca²⁺ permeability (P_Ca : P_Cs = 2) compared with that of WT-CALHM1.
(H) Cytoplasmic Ca²⁺ measurements in HT-22 cells transiently transfected with control vector and WT or P86L-mutated Myc-CALHM1. Cells were treated and results analyzed as in Fig. 3A (n = 3 independent experiments). Inset, WB of the corresponding cell lysates with anti-Myc antibody. (I) Peak of [Ca²⁺]_i measurements as in (H) expressed in Δ F/F₀ (*, P<0.001; Student’s t test).